Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STIMULUS MDS2: Sabatolimab (MBG453) + Azacitidine in Higher-Risk MDS/CMML-2
CTR20201781Phase 3Terminated
- Sponsor
- Novartis
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of sabatolimab in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), sponsored by Novartis. Started Sep 2020; status: terminated.
02
Drugs
sabatolimab
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on CTR20201781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201781.